Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, and member, Duke Cancer Institute, discusses the combination of ieramilimab (LAG525) and spartalizumab in advanced malignancies.
During the 2020 SITC Virtual Congress, investigators presented the results of an ongoing phase 2 multicenter trial evaluating the efficacy and safety of LAG525, a LAG-3 inhibitor, and spartalizumab, a PD-1 inhibitor.
The trial enrolled 235 patients with non–small cell lung cancer (n = 42), melanoma (n = 42), renal cell carcinoma (RCC; n = 38), mesothelioma (n = 57), and triple-negative breast cancer (n = 56).
In the RCC cohort, the overall response rate (ORR) was 26.3% in patients who had not received prior anti–PD-1/PD-L1 therapy and 5.3% in those previously treated with anti–PD-1/PD-L1 therapy.
Moreover, 5 patients with immunotherapy-naïve RCC achieved a partial response (PR), and 1 patient who was immunotherapy exposed achieved a PR with the combination.
Two patients with mesothelioma who were immunotherapy naïve and 1 patient with melanoma who had prior immunotherapy achieved complete responses with LAG525/spartalizumab, concludes Zhang.